DIGITAL-COOPERATION
27.5.2024 20:23:30 CEST | Business Wire | Press release
The Digital Cooperation Organization (DCO), a global multilateral organization committed to enabling digital prosperity for all by accelerating the sustainable and inclusive growth of the digital economy, announced the launch of EconomiX magazine, a publication offering insights from international digital economy thought leaders into ways nations and organizations can seize the digital economy’s opportunities to spur digital transformation globally. By merging insights from different stakeholders from the public and private sectors, academia, and international organizations from DCO Member States and other countries, EconomiX provides a holistic view of the digital economy from different perspectives.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240527424476/en/
1st Issue of the “EconomiX by the DCO” magazine (Graphic: AETOSWire)
The first edition of EconomiX covers a wide range of topics including global news on the digital economy, updates from DCO Member States, special articles on "Developing new AI business models" and "Digital upskilling -future-proof jobs". The theme of the magazine's first issue "Growth Unleashed - AI: Powering Economic Prosperity" delves into the world of artificial intelligence and its transformative impact on economies worldwide.
In addition to exclusive interviews with H.E. Dr. Bosun Tijani, Minister of Communications, Innovation and Digital Economy of the Federal Republic of Nigeria, and H.E. Paula Ingabire, Minister of Information and Communications Technology and Innovation of the Republic of Rwanda, and Ms. Deemah AlYahya, Secretary-General of the DCO, this issue features articles and interviews with a distinguished group of ministers, CEOs, and experts in technology and the digital economy.
Manel Bondi, DCO’s Chief of Digital Markets Growth, commented: "EconomiX stands as a catalyst for change and empowerment amidst the digital revolution. It fills an important gap with its focus on the economic dimension of technology as a key pillar to drive and sustain inclusive and meaningful economic growth across the globe. It demonstrates how communities, businesses, and governments can cooperate meaningfully and pave the way toward achieving digital prosperity for all. EconomiX is a platform that fosters knowledge sharing, innovation, and inspiration for our readers, and reflects our dedication to promoting cooperation to develop the global digital economy."
Addressing critical aspects of digital economic advancement like policy making, data transformation, digital updates, women empowerment, and thought leadership, EconomiX endeavors to guide its readers through the digital revolution. It aims to provide actionable insights, expert analysis, and case studies for navigating digital change, fostering an understanding of how to leverage digital transformation for economic and social prosperity.
The magazine is a vital tool for digital transformation, aimed at empowering change by fostering knowledge exchange, enhancing cooperation, uplifting social prosperity, and stimulating innovation. It presents global trends and innovations, advocates for inclusive digital transformation, and fosters a community of leaders shaping the digital future. It also highlights the DCO's impactful initiatives and showcases success stories from the network. Available in both digital and print formats, it is an invaluable resource for those committed to making a significant impact in the digital realm. https://www.dco.org/economix
Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240527424476/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom